Health Catalyst, Inc. (NASDAQ:HCAT – Get Free Report) General Counsel Benjamin Landry sold 29,478 shares of the stock in a transaction dated Thursday, November 12th. The stock was sold at an average price of $1.39, for a total value of $40,974.42. Following the transaction, the general counsel directly owned 251,894 shares in the company, valued at approximately $350,132.66. The trade was a 10.48% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.
Benjamin Landry also recently made the following trade(s):
- On Wednesday, November 11th, Benjamin Landry sold 70,000 shares of Health Catalyst stock. The shares were sold at an average price of $1.43, for a total value of $100,100.00.
Health Catalyst Price Performance
NASDAQ HCAT opened at $1.51 on Monday. The company has a market cap of $114.99 million, a P/E ratio of -0.53 and a beta of 1.52. The stock has a 50-day moving average of $1.69 and a two-hundred day moving average of $1.68. Health Catalyst, Inc. has a 1-year low of $0.96 and a 1-year high of $3.02.
Health Catalyst (NASDAQ:HCAT – Get Free Report) last issued its quarterly earnings results on Thursday, November 5th. The company reported ($0.03) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.02. Health Catalyst had a negative net margin of 74.24% and a negative return on equity of 4.84%. The company had revenue of $56.28 million for the quarter, compared to analyst estimates of $55.39 million. On average, analysts anticipate that Health Catalyst, Inc. will post -0.18 EPS for the current fiscal year.
Analyst Ratings Changes
Several analysts have recently issued reports on HCAT shares. Canaccord Genuity Group cut Health Catalyst from a “buy” rating to a “hold” rating and reduced their price objective for the company from $3.00 to $1.80 in a research note on Thursday, August 20th. Weiss Ratings restated a “sell (d-)” rating on shares of Health Catalyst in a report on Monday, October 26th. Wells Fargo & Company reduced their price objective on shares of Health Catalyst from $1.75 to $1.50 and set an “equal weight” rating on the stock in a report on Thursday, August 13th. Finally, Citigroup decreased their price objective on shares of Health Catalyst from $2.50 to $2.00 and set a “neutral” rating for the company in a research report on Tuesday, August 11th. Five research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Reduce” and an average target price of $2.01.
Institutional Inflows and Outflows
A number of hedge funds have recently made changes to their positions in HCAT. Palogic Value Management L.P. acquired a new stake in shares of Health Catalyst during the 2nd quarter worth about $9,796,000. BlackRock Inc. acquired a new position in Health Catalyst in the second quarter valued at approximately $3,654,000. Marshall Wace LLP acquired a new position in Health Catalyst in the third quarter valued at approximately $1,810,000. Mink Brook Asset Management LLC boosted its holdings in Health Catalyst by 25.4% in the third quarter. Mink Brook Asset Management LLC now owns 925,510 shares of the company’s stock valued at $1,601,000 after purchasing an additional 187,233 shares in the last quarter. Finally, Hsbc Holdings PLC purchased a new position in Health Catalyst in the second quarter valued at approximately $809,000. Hedge funds and other institutional investors own 85.00% of the company’s stock.
Health Catalyst Company Profile
Health Catalyst, Inc. provides data and analytics technology and services to healthcare organizations. Its solutions are designed to help providers use clinical, operational, and financial data to support decision-making and improve care delivery. The company’s offerings include a data platform that brings together information from multiple sources, analytics applications for healthcare workflows, and professional services. These services can include implementation, data management, and support for organizations developing and applying analytics programs.
Recommended Stories
- Five stocks we like better than Health Catalyst
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Health Catalyst Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Health Catalyst and related companies with MarketBeat.com's FREE daily email newsletter.
